LY03015 / Luye Group - LARVOL DELTA

A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Luye Pharma Group Ltd.

New P1 trial

Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015 (Luye Press Release) - "The clinical trial being conducted in the U.S. is an open-label, single-dose, and parallel-group bridging study designed to evaluate the safety, tolerability, and pharmacokinetic profile of LY03015 in healthy Chinese and Caucasian adults, providing key evidence to support dose selection for subsequent U.S. Phase Ⅱ and Phase Ⅲ clinical trials."

Trial status • Huntington's Disease

Mass Balance Study of [14C] LPM3770164 in Healthy Participants (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Genetic Disorders • Huntington's Disease • Movement Disorders

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Luye Pharma Group Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Movement Disorders

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.

New P1/2 trial • Movement Disorders

Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Luye Pharma Group Ltd. | Not yet recruiting ➔ Completed

Trial completion • Genetic Disorders • Huntington's Disease • Movement Disorders

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Luye Pharma Group Ltd. | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Huntington's Disease • Movement Disorders

Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Genetic Disorders • Huntington's Disease • Movement Disorders

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects (clinicaltrials.gov) - P1 | N=104 | Completed | Sponsor: Luye Pharma Group Ltd. | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Huntington's Disease • Movement Disorders

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Genetic Disorders • Huntington's Disease • Movement Disorders

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Luye Pharma Group Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2023 ➔ Oct 2023 | Trial primary completion date: Jan 2023 ➔ Oct 2023

Enrollment open • Trial completion date • Trial primary completion date • Genetic Disorders • Huntington's Disease • Movement Disorders